Agronomics Stock Price, News & Analysis

Welcome to our dedicated page for Agronomics news (Ticker: AGNMF), a resource for investors and traders seeking the latest updates and insights on Agronomics stock.

Agronomics Limited (AGNMF) is a London-listed investment company focused on clean food and cellular agriculture, and its news flow reflects activity across a portfolio of more than 20 private companies in this emerging field. Company announcements cover new investments, follow-on funding, portfolio milestones and periodic updates on net asset value, giving readers insight into how Agronomics is deploying capital and how its holdings are progressing.

Recent news has highlighted additional investments in precision fermentation businesses, such as funding for All G Co Holdings Pty Limited, which develops human and bovine milk proteins like lactoferrin without the use of animals. Agronomics has also reported further equity investment in BlueNalu, Inc., a cell-cultivated seafood company working on products such as cultivated bluefin tuna toro for premium foodservice markets.

Updates on other portfolio companies include Liberation Bioindustries, which is building a commercial-scale precision fermentation facility to produce bio-based protein and other ingredients, Geltor, Inc., which has received an FDA “no questions” letter confirming GRAS status for its vegan collagen polypeptide PrimaColl, Clean Food Group Limited, which manufactures sustainable oils and fats through fermentation, and Onego Bio, whose precision-fermented egg protein Bioalbumen has also received an FDA GRAS “no questions” letter.

News items may also cover less favourable developments, such as the dissolution of Meatable B.V., and periodic net asset value calculations that summarise the impact of portfolio movements and foreign exchange changes on Agronomics’ balance sheet. For investors and observers interested in cellular agriculture and alternative proteins, the Agronomics news stream provides regular, company-sourced updates on financing rounds, regulatory progress and commercial partnerships across this specialised investment portfolio.